Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $13.79.

Several brokerages have recently issued reports on MRNS. Oppenheimer reissued a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Truist Financial reissued a “buy” rating and set a $10.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday, June 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday, April 15th. Finally, Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday, April 16th.

Institutional Trading of Marinus Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MRNS. Sherbrooke Park Advisers LLC acquired a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $141,000. Schonfeld Strategic Advisors LLC raised its holdings in Marinus Pharmaceuticals by 69.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock worth $2,040,000 after purchasing an additional 103,935 shares in the last quarter. Eventide Asset Management LLC raised its holdings in Marinus Pharmaceuticals by 42.8% during the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock worth $36,466,000 after purchasing an additional 1,356,800 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Marinus Pharmaceuticals by 6.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock worth $23,381,000 after purchasing an additional 173,226 shares in the last quarter. Finally, Acuta Capital Partners LLC acquired a new stake in Marinus Pharmaceuticals during the third quarter worth approximately $157,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Trading Down 4.9 %

Shares of MRNS stock opened at $1.17 on Friday. The company has a debt-to-equity ratio of 5.68, a current ratio of 3.07 and a quick ratio of 2.93. The firm has a market cap of $64.27 million, a PE ratio of -0.44 and a beta of 1.11. The company has a 50-day moving average of $1.41 and a two-hundred day moving average of $6.46. Marinus Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, hitting the consensus estimate of ($0.68). The company had revenue of $7.68 million during the quarter, compared to analyst estimates of $8.61 million. Marinus Pharmaceuticals had a negative net margin of 513.80% and a negative return on equity of 518.13%. On average, analysts predict that Marinus Pharmaceuticals will post -1.87 EPS for the current year.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.